MannKind (MNKD) Set to Announce Earnings on Wednesday

MannKind (NASDAQ:MNKD) will issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.02 per share for the quarter.

MannKind (NASDAQ:MNKD) last announced its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.02. The firm had revenue of $58.47 million during the quarter, compared to the consensus estimate of $52.36 million. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Price Performance

Shares of MNKD stock traded down $0.02 on Thursday, hitting $4.32. 114,807 shares of the stock traded hands, compared to its average volume of 2,883,686. The company’s fifty day moving average is $4.38 and its 200 day moving average is $3.92. MannKind has a 1-year low of $3.17 and a 1-year high of $5.75. The company has a market capitalization of $1.17 billion, a PE ratio of -88.00 and a beta of 1.34.

Wall Street Analyst Weigh In

A number of equities analysts have commented on MNKD shares. Wedbush restated an “outperform” rating and issued a $10.00 target price on shares of MannKind in a research note on Wednesday, February 28th. HC Wainwright restated a “buy” rating and issued a $7.50 price target on shares of MannKind in a research note on Thursday, January 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $6.50 target price on shares of MannKind in a research report on Friday, March 15th.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.